Zealand Pharma A/S Q2 2024 Earnings Report $113.28 -1.32 (-1.15%) (As of 05:50 PM ET) Earnings HistoryForecast Zealand Pharma A/S EPS ResultsActual EPS-$0.67Consensus EPS -$0.61Beat/MissMissed by -$0.06One Year Ago EPSN/AZealand Pharma A/S Revenue ResultsActual Revenue$4.93 millionExpected Revenue$0.50 millionBeat/MissBeat by +$4.43 millionYoY Revenue GrowthN/AZealand Pharma A/S Announcement DetailsQuarterQ2 2024Date8/15/2024TimeN/AConference Call ResourcesZLDPF Earnings History Why is Buffett going all in on this? (Ad)Warren Buffett has increased his already massive stake in this sector by almost 30% in the past few months. Microsoft and Blackrock created a special fund worth $100 billion to boost this 'silent' bull market. Institutional investors have a combined $2.8 trillion in this sector. Despite its "bad rap", this industry stubbornly rakes in profits.Click here to learn more >>> Zealand Pharma A/S Earnings HeadlinesZealand Pharma announces first participant enrolled in ZUPREME-1December 12, 2024 | markets.businessinsider.comBerenberg Bank Sticks to Their Buy Rating for Zealand Pharma (ZLDPF)December 11, 2024 | markets.businessinsider.comU.S. Government: “this could save civilization.”Experts indicate that ChatGPT alone consumes up to 17,000 times more electricity than the average U.S. household uses in a single day. And with companies like Google and Microsoft implementing AI into everything we do, that energy consumption is only going to exponentially increase. Thing is, outside of a small group of elite investors, nobody has connected the dots on how this military contractor could be the most important company in the AI boom.December 18, 2024 | Porter & Company (Ad)Zealand Pharma starts Phase 2b trial for obesity drug candidate petrelintideDecember 10, 2024 | reuters.comZealand Pharma initiated with an Overweight at JPMorganNovember 8, 2024 | markets.businessinsider.comZealand Pharma’s 2024 Progress and Financial ResultsNovember 8, 2024 | markets.businessinsider.comSee More Zealand Pharma A/S Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Zealand Pharma A/S? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Zealand Pharma A/S and other key companies, straight to your email. Email Address About Zealand Pharma A/SZealand Pharma A/S (OTCMKTS:ZLDPF), a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglucagon that is in Phase III clinical trials for treating congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. The company was incorporated in 1997 and is based in Søborg, Denmark.View Zealand Pharma A/S ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles History Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of Earnings Upcoming Earnings Cintas (12/19/2024) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
